Endovascular Engineering ENGULF Study

Exclusion Criteria

• •Patients must be EXCLUDED from participation in this study if ANY of the following criteria are met:
• •1. \*Acute massive PE at presentation
• •2. \*Prior PE within last 6 months
• •3. \*Thrombolytic use within 30 days of baseline CTA
• •4. \*Pulmonary hypertension with peak pulmonary artery systolic pressure \> 70 mmHg by right heart catheterization
• •5. \*Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
• •6. \*FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
• •7. \*Hematocrit \< 28% (NOTE: hematocrit required within 24 hours of index procedure)
• •8. \*Platelets \< 100,000/μL
• •9. \*Serum creatinine \> 1.8 mg/dL
• •10. \*International normalized ratio (INR) \> 3
• •11. \*aPTT (or PTT) \> 50 seconds on no anticoagulation
• •12. \*Major trauma \< 14 days
• •13. \*Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
• •14. \*Cardiovascular or pulmonary surgery within last 7 days
• •15. \*Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
• •16. \*Known bleeding diathesis or coagulation disorder
• •17. \*Known left bundle branch block
• •18. \*History of severe pulmonary arterial hypertension
• •19. \*History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
• •20. \*History of uncompensated heart failure
• •21. \*History of underlying lung disease that is oxygen dependent
• •22. \*Presence of IVC filter and or iliocaval stents
• •23. \*History of heparin-induced thrombocytopenia (HIT)
• •24. \*Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
• •25. \*Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
• •26. \*Known allergy to any device component
• •27. (\*)Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot or non-clot embolus)
• •28. \*Life expectancy of \< 90 days, as determined by Investigator
• •29. \*Female who is pregnant or nursing
• •30. \*Current participation in another investigational drug or device treatment study